Skip to main content

Table 4 Univariable and multivariable association between baseline variable and clinical end-points

From: The importance of proteinuria and prior cardiovascular disease in all major clinical outcomes of atherosclerotic renovascular disease – a single-center observational study

 

Death

ESKDa

CVEa

Any

Univariable

Multivariable

Univariable

Multivariable

Univariable

Multivariable

Univariable

Multivariable

HR

95% CI

HR

95% CI

HR

95% CI

HR

95% CI

HR

95% CI

HR

95% CI

HR

95% CI

HR

95% CI

Ageb

1.48

(1.34–1.63)

1.38

(1.24–1.54)

1.36

(1.23–1.50)

1.17

(1.06–1.31)

1.29

(1.18–1.41)

1.21

(1.10–1.33)

1.22

1.12–1.33

1.09

(0.99–1.21)

Patency scorec

0.95

(0.90–0.99)

0.95

(0.90–1.00)

0.95

(0.90–0.98)

0.95

(0.90–0.98)

0.93

(0.90–0.98)

0.95

(0.93–1.01)

0.93

0.90–0.98

0.95

(0.93–1.00)

Revascularization

0.72

(0.58–0.90)

0.65

(0.51–0.83)

0.70

(0.57–0.87)

0.59

(0.46–0.76)

0.89

(0.73–1.09)

−

−

0.92

0.76–1.12

−

−

MVD

1.44

(1.20–1.73)

1.24

(1.02–1.50)

1.37

(1.15–1.65)

1.17

(0.97–1.42)

1.61

(1.35–1.91)

1.38

(1.15–1.65)

1.50

1.26–1.79

1.27

(1.06–1.52)

Diabetes

1.17

(0.99–1.39)

1.07

(0.89–1.28)

1.09

(0.92–1.30)

0.98

(0.81–1.17)

1.20

(1.02–1.41)

1.02

(0.86–1.21)

1.13

0.96–1.33

0.94

(0.79–1.12)

CHF

1.74

(1.43–2.11)

1.33

(1.08–1.64)

1.77

(1.46–2.14)

1.39

(1.13–1.71)

1.84

(1.53–2.21)

1.37

(1.11–1.68)

1.89

1.57–2.27

1.42

(1.16–1.75)

FPE

2.13

(1.56–2.91)

2.10

(1.50–2.92)

2.01

(1.48–2.73)

1.82

(1.31–2.51)

2.12

(1.56–2.88)

1.88

(1.36–2.60)

2.05

1.51–2.77

1.72

(1.24–2.38)

RAB

0.76

(0.65–0.89)

0.83

(0.70–0.98)

0.78

(0.66–0.92)

0.84

(0.71–1.00)

0.85

(0.73–0.99)

0.88

(0.75–1.03)

0.83

0.71–0.96

0.85

(0.73–1.00)

BB

0.84

(0.71–0.99)

0.93

(0.78–1.10)

0.85

(0.72–1.00)

0.89

(0.75–1.05)

0.84

(0.72–0.99)

0.90

(0.76–1.06)

0.88

0.75–1.03

0.92

(0.78–1.08)

Statin

0.80

(0.68–0.95)

0.79

(0.66–0.94)

0.81

(0.69–0.95)

0.79

(0.66–0.93)

0.93

(0.80–1.08)

0.92

(0.78–1.08)

0.91

0.78–1.06

0.90

(0.76–1.06)

MAPd

0.94

(0.90–0.98)

0.97

(0.92–1.02)

0.93

(0.90–0.98)

0.95

(0.90–1.00)

0.93

(0.90–0.98)

0.95

(0.91–1.00)

0.94

0.90–0.98

0.94

(0.90–0.99)

Proteinuriae (g/day)

1.12

(1.07–1.18)

1.14

(1.08–1.20)

1.13

(1.08–1.18)

1.14

(1.09–1.20)

1.09

(1.04–1.14)

1.10

(1.05–1.16)

1.11

1.06–1.16

1.12

(1.07–1.18)

eGFRf (ml/min/1.73 m2)

0.89

(0.87–0.91)

0.92

(0.89–0.94)

0.86

(0.84–0.89)

0.89

(0.86–0.91)

0.92

(0.89–0.94)

0.94

(0.92–0.97)

0.90

0.88–0.92

0.92

(0.89–0.94)

  1. BB beta blocker, CHF congestive heart failure, CI confidence interval, CVE cardiovascular event, eGFR estimated glomerular filtration rate, ESKD end-stage kidney disease, FPE flash pulmonary oedema, HR hazard ratio, MAP mean arterial pressure, MVD macrovascular disease, RAB renin-angiotensin blockade. Bold data indicates a statistically significant association with a p value less than 0.05
  2. aAdjusted for death
  3. bPer 10 year increase
  4. cPer 25 unit increase in patency score
  5. dPer 10 mmHg increase in MAP
  6. ePer 1 g/day increase in proteinuria
  7. fPer 5 ml/min/1.73 m2 increase in eGFR, calculated using the Chronic Kidney Disease Epidemiology collaboration equation (CKD-EPI)11
Back to article page

BMC Nephrology

ISSN: 1471-2369

Contact us